MedTrace Logo

Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea

NCT04419259 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-06-11

No results posted yet for this study

Summary

An exploratory open-label study of rosacea patients to study the efficacy and tolerability of erenumab in the prophylactic treatment of persistent redness and flushing attributed to rosacea. Approximately 30 subjects will be included in the study and receive erenumab 140 mg for three months. The study will begin June 2020 and is expected to last nine months.

Conditions

  • Rosacea

Interventions

DRUG

AMG 334

30 subjects with rosacea will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)

Sponsors & Collaborators

  • Danish Headache Center

    collaborator OTHER

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • Herlev and Gentofte Hospital

    collaborator OTHER

  • Messoud Ashina

    lead OTHER

Principal Investigators

  • Messoud Ashina, Professor · Danish Headache Center

  • Nita KF Wienholtz, MD · Danish Headache Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-09
Primary Completion
2021-03-31
Completion
2021-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04419259 on ClinicalTrials.gov